Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic Rapamycin to Prevent In-Stent Restenosis
NCT02365415Phase 2Withdrawn
- Sponsor
- Boston Children's Hospital
- Start
- Feb 2015
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sirolimus in in-stent restenosis (ISR), sponsored by Boston Children's Hospital. Planned start Feb 2015; status: withdrawn.
02
Drugs
sirolimus
03
Conditions
in-stent restenosis (ISR)
Beyond the preview
Go deeper on NCT02365415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02365415.